Literature DB >> 14595690

Proteomic analysis of the tumorigenic human prostate cell line M12 after microcell-mediated transfer of chromosome 19 demonstrates reduction of vimentin.

Xuhui Liu1, Yongzhong Wu, Zendra E Zehner, Colleen Jackson-Cook, Joy L Ware.   

Abstract

Critical alterations in proteins that accompany or control the aggressiveness of human prostate cancers remain poorly defined. Previously we demonstrated that the highly tumorigenic, metastatic human prostate cell line M12 was converted to a slow growing, poorly tumorigenic cell line by introduction of an intact human chromosome 19, generating the M12 (F6) hybrid cells. The objective of this report was to identify changes in the protein profile of these M12(F6) microcell hybrid cells. A combination of two-dimensional gel electrophoresis and matrix assisted laser desorption-time of flight-mass spectroscopy was used to compare proteins made by these two cell lines. No consistently increased proteins were identified. However, seven proteins were reproducibly reduced more than twofold: vimentin, hsp90, ATP synthase, 26S protease regulatory subunit, heterogeneous nuclear ribonucleoprotein, T-Complex protein 1 beta, and alpha-1 tubulin. The striking reduction in vimentin protein was accompanied by significantly decreased vimentin mRNA, revealed by Northern blotting. Our findings implicate reduced vimentin in the conversion of these tumorigenic prostate epithelial cells into slow growing, less aggressive cells. These studies demonstrate that application of proteomic analysis to specific problems in an experimental context can yield biologically relevant information about the prostate cancer cell phenotype.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14595690     DOI: 10.1002/elps.200305574

Source DB:  PubMed          Journal:  Electrophoresis        ISSN: 0173-0835            Impact factor:   3.535


  8 in total

1.  TGFbeta1 regulation of vimentin gene expression during differentiation of the C2C12 skeletal myogenic cell line requires Smads, AP-1 and Sp1 family members.

Authors:  Yongzhong Wu; Xueping Zhang; Morgan Salmon; Xia Lin; Zendra E Zehner
Journal:  Biochim Biophys Acta       Date:  2006-12-06

2.  Comparative proteomic and radiobiological analyses in human lung adenocarcinoma cells.

Authors:  Rui Wei; Yingjin Zhang; Liangfang Shen; Wuzhong Jiang; Cui Li; Meizuo Zhong; Yun Xie; Dingyi Yang; Lili He; Qing Zhou
Journal:  Mol Cell Biochem       Date:  2011-08-06       Impact factor: 3.396

3.  MicroRNA-17-3p is a prostate tumor suppressor in vitro and in vivo, and is decreased in high grade prostate tumors analyzed by laser capture microdissection.

Authors:  Xueping Zhang; Amy Ladd; Ema Dragoescu; William T Budd; Joy L Ware; Zendra E Zehner
Journal:  Clin Exp Metastasis       Date:  2009-09-22       Impact factor: 5.150

4.  Inhibition of vimentin or beta1 integrin reverts morphology of prostate tumor cells grown in laminin-rich extracellular matrix gels and reduces tumor growth in vivo.

Authors:  Xueping Zhang; Marcia V Fournier; Joy L Ware; Mina J Bissell; Adly Yacoub; Zendra E Zehner
Journal:  Mol Cancer Ther       Date:  2009-03-10       Impact factor: 6.261

5.  Periostin identified as a potential biomarker of prostate cancer by iTRAQ-proteomics analysis of prostate biopsy.

Authors:  Guowei Xia; Qiang Ding; Chuanyu Sun; Chao Song; Zhicheng Ma; Ke Xu; Yang Zhang; Hong Jin; Shijun Tong; Weihong Ding
Journal:  Proteome Sci       Date:  2011-04-19       Impact factor: 2.480

6.  Prognostic significance and biological function of Lamina-associated polypeptide 2 in non-small-cell lung cancer.

Authors:  Chang Liu; Hui Yu; Xuxia Shen; Jie Qiao; Xianghua Wu; Jianhua Chang; Xunxia Zhu; Jialei Wang; Xiaoyong Shen
Journal:  Onco Targets Ther       Date:  2019-05-16       Impact factor: 4.147

7.  Differential tissue-specific protein markers of vaginal carcinoma.

Authors:  K Hellman; A A Alaiya; S Becker; M Lomnytska; K Schedvins; W Steinberg; A-C Hellström; S Andersson; U Hellman; G Auer
Journal:  Br J Cancer       Date:  2009-03-24       Impact factor: 7.640

8.  miR-9 Acts as an OncomiR in Prostate Cancer through Multiple Pathways That Drive Tumour Progression and Metastasis.

Authors:  S J Seashols-Williams; W Budd; G C Clark; Q Wu; R Daniel; E Dragoescu; Z E Zehner
Journal:  PLoS One       Date:  2016-07-22       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.